Abbott Acquires A Future For Its Diabetes Care Business; Where’s Bayer?
This article was originally published in The Gray Sheet
Executive Summary
Access to a development partnership with insulin infusion pump manufacturer Smiths Medical could prove a critical component of Abbott Labs' $1.2 bil. purchase of diabetes management firm TheraSense
You may also be interested in...
Medtronic, Smiths Medical settle
Insulin pump cross-licensing agreement closes all pending litigation between the firms and allows retention of existing device designs, Smiths Medical announces July 1. "This agreement allows both companies to continue business as usual without having to change any of the features or functionality" of the pumps, a release states. In August 2004, Medtronic filed against Smiths alleging that the Deltec Cozmo insulin pump infringed certain MiniMed patents (1"The Gray Sheet" Jan. 19, 2004, p. 3)...
Medtronic, Smiths Medical settle
Insulin pump cross-licensing agreement closes all pending litigation between the firms and allows retention of existing device designs, Smiths Medical announces July 1. "This agreement allows both companies to continue business as usual without having to change any of the features or functionality" of the pumps, a release states. In August 2004, Medtronic filed against Smiths alleging that the Deltec Cozmo insulin pump infringed certain MiniMed patents (1"The Gray Sheet" Jan. 19, 2004, p. 3)...
Diabetes Care Growth Prospects Detailed By Abbott; Prism In Sight
Abbott's diabetes care unit will develop into a $1 bil. business within the next two years, according to VP-Investor Relations John Thomas